Arrowhead Pharmaceuticals, Inc. Share Price

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 18/07/2024 BST 5-day change 1st Jan Change
27.64 USD -1.36% Intraday chart for Arrowhead Pharmaceuticals, Inc. -2.16% -9.67%
Sales 2024 * 107M 8.3B Sales 2025 * 161M 12.42B Capitalization 3.43B 266B
Net income 2024 * -360M -27.85B Net income 2025 * -319M -24.68B EV / Sales 2024 * 29.1 x
Net cash position 2024 * 305M 23.6B Net cash position 2025 * 157M 12.11B EV / Sales 2025 * 20.4 x
P/E ratio 2024 *
-8.81 x
P/E ratio 2025 *
-10.3 x
Employees 525
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.53%
More Fundamentals * Estimated data
Dynamic Chart
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating MT
Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study MT
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial CI
Sector Update: Health Care Stocks Advance Monday Afternoon MT
Arrowhead Says Potential Obesity Treatment Shows 'Promising' Preclinical Results -- Shares Rise MT
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
Arrowhead Pharmaceuticals' Plozasiran Lowers Triglycerides in Phase 3 Trial; Shares Rise MT
Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome CI
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia CI
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients MT
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma CI
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM
More news

Latest transcript on Arrowhead Pharmaceuticals, Inc.

1 day-1.36%
1 week-2.16%
Current month+6.35%
1 month+17.24%
3 months+22.25%
6 months-16.65%
Current year-9.67%
More quotes
1 week
27.22
Extreme 27.22
30.41
1 month
23.01
Extreme 23.01
30.41
Current year
21.39
Extreme 21.39
39.83
1 year
20.67
Extreme 20.67
39.83
3 years
20.67
Extreme 20.67
84.83
5 years
19.51
Extreme 19.5101
93.66
10 years
1.20
Extreme 1.2
93.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 30/11/07
Director of Finance/CFO 57 31/12/08
Chief Tech/Sci/R&D Officer - 31/07/22
Members of the board TitleAgeSince
Chairman 71 22/11/10
Director/Board Member 64 18/12/11
Director/Board Member 79 31/08/20
More insiders
Date Price Change Volume
18/07/24 27.64 -1.36% 967,822
17/07/24 28.02 -5.15% 1,317,187
16/07/24 29.54 +2.36% 1,394,144
15/07/24 28.86 +2.67% 768,679
12/07/24 28.11 -0.50% 809,668

Delayed Quote Nasdaq, July 18, 2024 at 09:00 pm

More quotes
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
27.64 USD
Average target price
50.29 USD
Spread / Average Target
+81.93%
Consensus